AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26009922 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone block grafting
Number of subjects: 30
Study 23143753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 24
Study 23143753 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 24
Study 21676892 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 0
Study 21676892 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine mixed with dexamethasone 8 mg
Number of subjects: 0
Study 21676892 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 21676892 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine mixed with dexamethasone 8 mg
Number of subjects: 0
Study 19706108 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser therapy with topical 1% pimecrolimus cream twice daily (group A)
Number of subjects: 49
Study 19706108 — intervention group
Group type: COMPARATOR
Intervention: Excimer laser therapy twice per week (group B)
Number of subjects: 49
Study 16425615 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 0
Study 16425615 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading books
Number of subjects: 0
Study 16425615 — intervention group
Group type: EXPERIMENTAL
Intervention: Doing crosswords
Number of subjects: 0
Study 16425615 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 0
Study 16425615 — intervention group
Group type: COMPARATOR
Intervention: Presurgery condition
Number of subjects: 0
Study 14704801 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous explosive strength training (11-week duration)
Number of subjects: 19
Study 14704801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 11306521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/d (n=35)
Number of subjects: 52
Study 11306521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 52
Study 7745014 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU human urinary FSH (uFSH) administered subcutaneously (sc)
Number of subjects: 10
Study 7745014 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU human urinary FSH (uFSH) administered subcutaneously (sc)
Number of subjects: 10
Study 7745014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose administration of either 75 or 150 IU uFSH, sc
Number of subjects: 10
Study 2244794 — intervention group
Group type: EXPERIMENTAL
Intervention: High delta sleep ratio
Number of subjects: 74
Study 2244794 — intervention group
Group type: COMPARATOR
Intervention: Low delta sleep ratio
Number of subjects: 74
Study 343969 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic nitrogen analog of tetrahydrocannabinol (NIB)
Number of subjects: 0
Study 343969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 343969 — intervention group
Group type: COMPARATOR
Intervention: 50 mg codeine phosphate
Number of subjects: 0
Study 343969 — intervention group
Group type: COMPARATOR
Intervention: 50 mg secobarbital
Number of subjects: 0
Study 31628490 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly followed by placebo (n=19)
Number of subjects: 167
Study 31628490 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab following denosumab (n=16)
Number of subjects: 167
Study 31628490 — intervention group
Group type: COMPARATOR
Intervention: Initial treatment with Romosozumab 210 mg monthly
Number of subjects: 167
Study 29102158 — intervention group
Group type: EXPERIMENTAL
Intervention: N'Durance® Dimer Flow (ND)
Number of subjects: 50
Study 29102158 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek™ Supreme XTE Flow (FS)
Number of subjects: 50
Study 29102158 — intervention group
Group type: COMPARATOR
Intervention: Both ND and FS
Number of subjects: 50
Study 25661462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling treatment of a single active MTrP
Number of subjects: 56
Study 23382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg) taken in the evening
Number of subjects: 75
Study 23382539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular polypill taken in the morning
Number of subjects: 75
Study 23382539 — intervention group
Group type: COMPARATOR
Intervention: Identically dosed agents in separate pills taken at different time points during the day
Number of subjects: 75
Study 22871107 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support program (SMP)
Number of subjects: 160
Study 22871107 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (Control)
Number of subjects: 160
Study 20129531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 99
Study 20129531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 17879926 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplification strategy using a boosted protease inhibitor (PI) alone
Number of subjects: 0
Study 17879926 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) strategy
Number of subjects: 0
Study 17879926 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplification strategy
Number of subjects: 0
Study 16252435 — intervention group
Group type: EXPERIMENTAL
Intervention: Coin in the Hand Test (CIH)
Number of subjects: 40
Study 16252435 — intervention group
Group type: EXPERIMENTAL
Intervention: Wechsler Mental Control Test (MCT)
Number of subjects: 40
Study 16252435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey I 5‐Item Test (RIT)
Number of subjects: 40
Study 16252435 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Index (AMI)
Number of subjects: 40
Study 16252435 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed to simulate head injury performance (N = 40)
Number of subjects: 40
Study 16252435 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed to do their best (N = 40)
Number of subjects: 40
Study 12014939 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone access to MRI requests
Number of subjects: 414
Study 12014939 — intervention group
Group type: COMPARATOR
Intervention: Written access to MRI requests
Number of subjects: 414
Study 12014939 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based seminar for guideline dissemination
Number of subjects: 414
Study 12014939 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-specific audit feedback for guideline dissemination
Number of subjects: 414
Study 12014939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both seminar and feedback for guideline dissemination
Number of subjects: 414
Study 12014939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seminar or feedback) for guideline dissemination
Number of subjects: 414
Study 10469040 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of oral terfenadine
Number of subjects: 44
Study 10469040 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 microg of inhaled ipratropium bromide
Number of subjects: 44
Study 10469040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 8681154 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 20 (20 reps of 20% of 1 RM)
Number of subjects: 57
Study 8681154 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 40 (10 reps of 40% of 1 RM)
Number of subjects: 57
Study 8681154 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 60 (7 reps of 60% of 1 RM)
Number of subjects: 57
Study 8681154 — intervention group
Group type: COMPARATOR
Intervention: Control group (aerobic training only)
Number of subjects: 57
Study 1852278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramco latex agglutination test
Number of subjects: 51
Study 1852278 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable medical problems)
Number of subjects: 51
Study 6341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (Chymodiactin)
Number of subjects: 108
Study 6341632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 6341632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after failure)
Number of subjects: 108
Study 30784555 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (3·75 mg/day)
Number of subjects: 3747
Study 30784555 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 3747
Study 30784555 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 3747
Study 30784555 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3747
Study 28727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater physical activity level at baseline
Number of subjects: 103
Study 28727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in 1 additional hour per day of moderate activity
Number of subjects: 103
Study 28727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater physical activity level at baseline (after controlling for other variables)
Number of subjects: 103
Study 26729431 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy × 5
Number of subjects: 203
Study 26729431 — intervention group
Group type: COMPARATOR
Intervention: 3 Gy × 10
Number of subjects: 203
Study 25115285 — intervention group
Group type: EXPERIMENTAL
Intervention: Avena Rhealba(®) extract and hyaluronic acid (Product A)
Number of subjects: 21
Study 25115285 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference product B
Number of subjects: 21
Study 25115285 — intervention group
Group type: COMPARATOR
Intervention: Reference product C
Number of subjects: 21
Study 25115285 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 21
Study 25115285 — intervention group
Group type: EXPERIMENTAL
Intervention: All three products (A, B, C)
Number of subjects: 21
Study 22501080 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic simulations of unilateral CI
Number of subjects: 0
Study 22501080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal (CI+HA) hearing
Number of subjects: 0
Study 19575814 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery by-pass grafting without the use of cardiopulmonary by-pass (CPB) and aortic cross-clamping
Number of subjects: 0
Study 19575814 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery by-pass grafting with the use of cardiopulmonary by-pass (CPB) and aortic cross-clamping
Number of subjects: 0
Study 18093949 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere (LH)
Number of subjects: 0
Study 18093949 — intervention group
Group type: COMPARATOR
Intervention: Right hemisphere (RH)
Number of subjects: 0
Study 18093949 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handed subjects
Number of subjects: 0
Study 18093949 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Number of subjects: 0
Study 15577620 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 21
Study 15577620 — intervention group
Group type: COMPARATOR
Intervention: HAART alone (Control)
Number of subjects: 21
Study 11161546 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing n-6 and n-3 LCP from purified phospholipids (LCP-F)
Number of subjects: 34
Study 11161546 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (F)
Number of subjects: 34
Study 11161546 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 34
Study 11161546 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 34
Study 9679818 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg/day for 7-14 days)
Number of subjects: 163
Study 9679818 — intervention group
Group type: COMPARATOR
Intervention: Atgam (15 mg/kg/day for 7-14 days)
Number of subjects: 163
Study 9679818 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 163
Study 9679818 — intervention group
Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 163
Study 9679818 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin and Atgam
Number of subjects: 163
Study 9609638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCRT (78 Gy conformal radiotherapy)
Number of subjects: 101
Study 9609638 — intervention group
Group type: COMPARATOR
Intervention: Conven-RT (70 Gy conventional radiotherapy)
Number of subjects: 101
Study 9609638 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 101
Study 2566160 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (new beta 2-agonist)
Number of subjects: 0
Study 2566160 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (control)
Number of subjects: 0
Study 334356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 334356 — intervention group
Group type: COMPARATOR
Intervention: Chlorotrianisene
Number of subjects: 0
Study 31401140 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir for 12 weeks (group A)
Number of subjects: 177
Study 31401140 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir for 16 weeks (group B)
Number of subjects: 177
Study 31401140 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir plus Ribavirin for 12 weeks (group C)
Number of subjects: 177
Study 31401140 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and Pibrentasvir for 16 weeks (group D)
Number of subjects: 177
Study 29265085 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin
Number of subjects: 64
Study 29265085 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 64
Study 25555173 — intervention group
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate 0.5%/tobramycin 0.3% (Zylet)
Number of subjects: 32
Study 25555173 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone 0.1%/tobramycin 0.3% (Tobradex)
Number of subjects: 32
Study 23706046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (64 nmol/kg/min)
Number of subjects: 18
Study 23706046 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 23706046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion
Number of subjects: 18
Study 22007990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) 500/200 mg twice daily
Number of subjects: 39
Study 22007990 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir (DRV/r) 600/100 mg twice daily
Number of subjects: 39
Study 19768804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized rhDNase twice daily for 2 weeks
Number of subjects: 40
Study 19768804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16796545 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (SS)
Number of subjects: 6
Study 16796545 — intervention group
Group type: COMPARATOR
Intervention: Nebulized budesonide (ICS)
Number of subjects: 6
Study 15558250 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar stimulation (high-voltage electric stimuli with an anode on the ipsilateral mastoid process and a cathode over the contralateral process)
Number of subjects: 9
Study 15558250 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed current of conditioning stimulus
Number of subjects: 9
Study 15558250 — intervention group
Group type: EXPERIMENTAL
Intervention: Same (anodal) conditioning stimuli
Number of subjects: 9
Study 11143509 — intervention group
Group type: EXPERIMENTAL
Intervention: Longmire‐Interposition with pouch
Number of subjects: 49
Study 11143509 — intervention group
Group type: EXPERIMENTAL
Intervention: Longmire‐Interposition without pouch
Number of subjects: 49
Study 11143509 — intervention group
Group type: COMPARATOR
Intervention: Roux‐en‐Y‐reconstruction
Number of subjects: 49
Study 9266780 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy (INR 2.7 +/‐ 1.3)
Number of subjects: 76
Study 9266780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 9266780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR 1.3 +/‐ 0.08)
Number of subjects: 76
Study 9266780 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity warfarin (INR 2.3 +/‐ 1.1)
Number of subjects: 76
Study 8277435 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% potassium nitrate-zinc oxide eugenol temporary cement
Number of subjects: 0
Study 3539165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 3539165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30632718 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced antenatal counseling
Number of subjects: 404
Study 30632718 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal counseling
Number of subjects: 404
Study 26980363 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 396
Study 26980363 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 396
Study 25324541 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of smoking validated by serum cotinine levels
Number of subjects: 626
Study 25324541 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 626
Study 25324541 — intervention group
Group type: EXPERIMENTAL
Intervention: Never or past smokers
Number of subjects: 626
Study 25324541 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 626
Study 22545431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 100
Study 22545431 — intervention group
Group type: COMPARATOR
Intervention: Regular control paste
Number of subjects: 100
Study 20452432 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 microg antigen dose
Number of subjects: 3697
Study 20452432 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 microg paediatric dose
Number of subjects: 3697
Study 20452432 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME‐IMMUN paediatric vaccine formulation
Number of subjects: 3697
Study 17565457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g iv/12 h plus metronidazole 500 mg/8 h
Number of subjects: 122
Study 17565457 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin 500 mg iv/6 h
Number of subjects: 122
Study 16022166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive covariate adjustment
Number of subjects: 0
Study 16022166 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate transformation
Number of subjects: 0
Study 16022166 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression modeling approach
Number of subjects: 0
Study 12117888 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EPT)
Number of subjects: 111
Study 12117888 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic intervention (non-EPT)
Number of subjects: 111
Study 9935011 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful angioplasty with abrupt vessel closure
Number of subjects: 3899
Study 7557868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg per os once a week for 6 months
Number of subjects: 60
Study 7557868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2228932 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 41
Study 2228932 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 41
Study 2228932 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication groups (Alprazolam and Imipramine combined)
Number of subjects: 41
Study 2228932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 29737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for Primary Aldosteronism (PA) in hypertensive patients with spontaneous or diuretic-induced hypokalemia and resistant hypertension
Number of subjects: 0
Study 29737255 — intervention group
Group type: COMPARATOR
Intervention: Screening for Primary Aldosteronism (PA) in all hypertensive patients
Number of subjects: 0
Study 28460449 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 60
Study 28460449 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 60
Study 26220257 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment for 20-30 minutes before vaccination
Number of subjects: 60
Study 26220257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology treatment)
Number of subjects: 60
Study 26220257 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment
Number of subjects: 60
Study 24693675 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (Rabeprazole 20 mg once a day)
Number of subjects: 18
Study 24693675 — intervention group
Group type: COMPARATOR
Intervention: Histamine H2 receptor antagonist (Famotidine 20 mg twice a day)
Number of subjects: 18
Study 21205246 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hemicraniectomy within 48 hours after symptom onset
Number of subjects: 160
Study 21205246 — intervention group
Group type: COMPARATOR
Intervention: Maximum conservative treatment alone
Number of subjects: 160
Study 19663519 — intervention group
Group type: COMPARATOR
Intervention: TRC4186 250-2500 mg single dose
Number of subjects: 0
Study 19663519 — intervention group
Group type: COMPARATOR
Intervention: TRC4186 500-2000 mg multiple doses (twice daily for 6 days)
Number of subjects: 0
Study 19663519 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC4186 500 mg (fasted) vs 500 mg (fed)
Number of subjects: 0
Study 19663519 — intervention group
Group type: COMPARATOR
Intervention: TRC4186 500 mg followed by 1000 mg after 7-day washout in elderly subjects
Number of subjects: 0
Study 16441520 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 16441520 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (CAB)
Number of subjects: 0
Study 16441520 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole vs. CAB
Number of subjects: 0